IXICO PLC — Remuneration Information 2017

Aug 8, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4442N

IXICO plc

08 August 2017

8 August 2017

IXICO plc

("IXICO" or the "Company")

Share option grant

IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the digital technologies company serving neuroscience,  announces a grant of options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a price of 34p (being the closing middle market price per ordinary share on 7 August 2017).

The award of options under the Plan is subject to certain performance conditions and the options granted will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction occurring within three years of the date of grant.

The total number of options being issued at this time is 713,940 and includes a grant of options to Susan Lowther, Chief Financial Officer of the Company, as follows:

Name of Director	Number of options granted	Total number of options held	Percentage of issued share capital under option
Susan Lowther	235,000	545,196	2.01%

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer and Company Secretary	Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield /James Wolfe	Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: +44 20 3727 1000

About IXICO

IXICO is the digital technologies company serving neuroscience.  Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.  Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEVLFBDVFLBBL